NCT07301281 Trial of the "Mittin" Intervention to Improve Contraceptive Side Effect Counseling and Follow-up in Ethiopia
| NCT ID | NCT07301281 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Contraception |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,715 participants |
| Start Date | 2026-02-23 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,715 participants in total. It began in 2026-02-23 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if the "Mittin" intervention can improve women's ability to manage their fertility in line with their preferences among women aged 15-49 using hormonal contraceptives or intrauterine devices and attending public health centers in Addis Ababa, Ethiopia. The main question it aims to answer is: Does the Mittin intervention increase preference-aligned fertility management, contraceptive method satisfaction, and preferred contraceptive method use among participants compared to standard care? Researchers will compare women's outcomes in health centers providing the Mittin intervention to women's outcomes in health centers that offer standard care to see if Mittin improves women's ability to act in line with their contraceptive preferences. Participants will * Receive either standard contraception services (control arm) or enhanced services (intervention arm) * Participate in a survey at the beginning of the study * Participate in surveys 4 and 8 months later
Eligibility Criteria
Inclusion Criteria: * Woman * Started or continued using hormonal contraceptive method or copper IUD on day of recruitment * Ages 15-49 years * Willing to provide phone number and receive follow-up phone call Exclusion Criteria: * Not planning to live in Addis Ababa for the next eight months * Can not verbally communicate * Not willing to provide consent for the study
Contact & Investigator
Kelsey Holt, ScD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07301281 clinical trial?
This trial is open to female participants only, aged 15 Years or older, up to 49 Years, studying Contraception. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07301281 currently recruiting?
Yes, NCT07301281 is actively recruiting participants. Contact the research team at kelsey.holt@ucsf.edu for enrollment information.
Where is the NCT07301281 trial being conducted?
This trial is being conducted at Addis Ababa, Ethiopia.
Who is sponsoring the NCT07301281 clinical trial?
NCT07301281 is sponsored by University of California, San Francisco. The principal investigator is Kelsey Holt, ScD at University of California, San Francisco. The trial plans to enroll 2,715 participants.